[TSX Venture Exchange] Sonoma Pharmaceuticals, Inc. (SNOA) +25.81% : Pre-market : Sonoma Pharmaceuticals (SNOA) to Release Earnings on Thursday (2025-03-11)

Company Logo

Sonoma Pharmaceuticals, Inc. (SNOA)


SNOA Chart as of 2025-03-11

SNOA Chart


Stock Information

CEO:
CFO:
Employees: 10
Address: 5445 Conestoga Court, Boulder, CO, United States
Country: United States
Website: https://sonomapharma.com
Listing Date:
Founded:
Founder:
Current Price: 3.51 USD
Today Change: 25.81%
Outstanding Shares: 1,615,760
Volume: 34,908,163
Avg Volume: 677,200
Expert Target Price: 17.0000
(Institutions: 0)
EPS:
PER:
Dividend Date: 2019-06-20
Last Split Date: 2024-08-30
Last Split Factor: 1:20

Key Executives

Name Title Pay Year
Ms. Amy M. Trombly J.D. CEO, President & Director 608.82k
Mr. Jerome J. Dvonch CPA Chief Financial Officer 268.79k
Mr. Bruce Thornton Executive VP, COO & Corporate Secretary 540.94k
Mr. John Dal Poggetto Controller 433.36k

Financials

Income Statement

Metric Amount
Total Revenue 12,735,000
Cost Of Revenue 7,990,000
Gross Profit 4,745,000
Operating Income -4,701,000
Net Income -4,835,000

Balance Sheet

Metric Amount
Total Assets 14,740,000
Total Liabilities
Total Stockholder Equity

Cash Flow

Metric Amount
Total Cash From Operating Activities
Capital Expenditures

SEC Filings (Gemini Summaries)

AccNo Date Summary
0001683168-25-000736 2025-02-05 Sonoma Pharmaceuticals’ Q3 2025 10-Q filing (false) includes financial data for periods ending 2023/03-2024/12. Key items: Common Stock, APIC, Retained Earnings, AOCI, Stock Options, Restricted Stock, and Insurance Premium Financing. Also includes Equity Distribution Agreement.
0001683168-25-000611 2025-01-30 Sonoma Pharma (SNOA) filed an 8-K on 1/29/25, reporting a material supply agreement with WellSpring for Microcyn products. The 2-year agreement has automatic renewal options. The filing includes forward-looking statements and associated risks.
0001683168-25-000084 2025-01-03 SEC Form 4 filing by Bruce Thornton, Executive VP & COO of Sonoma Pharmaceuticals (SNOA), on 01/02/2025. It reports changes in beneficial ownership of securities. The filing indicates direct ownership and may involve a 10b5-1 trading plan.
0001683168-25-000083 2025-01-03 Form 4 filing for Sonoma Pharmaceuticals (SNOA) by director Jay E Birnbaum. Earliest transaction date: 01/02/2025. Form indicates changes in beneficial ownership of securities.
0001683168-25-000082 2025-01-03 SEC Form 4 filing for Sonoma Pharmaceuticals (SNOA) by Director John McLaughlin. Reports changes in beneficial ownership of securities, pursuant to Section 16(a). Earliest transaction date: 01/02/2025.

News Summary

Sonoma Pharmaceuticals (SNOA) to Release Earnings on Thursday
2025-02-11 07:36:44 | ETF Daily News
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect Sonoma Pharmaceuticals to post earnings of ($0.80) per share and revenue of $4.39 …
Link



Analysis of Today’s Move

**Sonoma Pharmaceuticals (SNOA) Stock Rally Analysis**

Sonoma Pharmaceuticals’ stock experienced a rally today, likely driven by a combination of factors. The anticipation of upcoming earnings, coupled with recent positive developments, may have fueled investor optimism. The earnings release scheduled for Thursday, February 13th, is undoubtedly a key factor. Investors are likely positioning themselves ahead of the announcement.

The expected earnings per share (EPS) is projected to be a loss of $0.80. Revenue estimates stand at $4.39 million. Despite the anticipated loss, positive news regarding supply agreements could be influencing sentiment. The recent material supply agreement with WellSpring is noteworthy.

The 8-K filing from January 29th highlighted a 2-year agreement. This agreement is for the supply of Microcyn products. The agreement includes automatic renewal options. This indicates potential long-term revenue stability for Sonoma Pharmaceuticals.

Furthermore, recent Form 4 filings revealed changes in beneficial ownership by executives and directors. These filings often signal insider confidence in the company’s future prospects. Bruce Thornton, Jay E Birnbaum, and John McLaughlin all reported changes. These filings add to the positive sentiment surrounding the stock.

In conclusion, the rally in Sonoma Pharmaceuticals’ stock today can be attributed to a confluence of factors. These factors include the upcoming earnings release, a new material supply agreement, and insider activity. Investors appear to be betting on a positive outlook for the company. This is despite the expected loss per share being reported on Thursday.


This stock has shown a change of 25.81% today.
Please consider that all investment decisions carry risk;
none of the content here should be construed as financial advice.
Always do your own research or consult a professional before making investment decisions.

The information provided in this article is for informational purposes only
and does not constitute legal, tax, or investment advice.
Investing involves risk, including the potential loss of principal.

Posted by

in

Leave a Reply

Your email address will not be published. Required fields are marked *